There are five FDA‐approved agents for managing hematopoietic acute radiation sickness (H‐ARS): Neupogen (G‐CSF), Neulasta (PEGylated G‐CSF), Udenyca (biosimilar to Neulasta), Leukine (GM‐CSF) and Nplate (thrombopoietin analog). The gene discussed is THPO; the disease is Axenfeld-Rieger syndrome.